NCT00210743View on ClinicalTrials.gov

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

October 31, 2005

Conditions
AnemiaKidney Diseases
Interventions
DRUG

epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210743 - Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia. | Biotech Hunter | Biotech Hunter